GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

zansecimab   Click here for help

GtoPdb Ligand ID: 11334

Synonyms: LY-3127804 | LY3127804
Compound class: Antibody
Comment: Zansecimab (LY3127804) is a humanised IgG4 monoclonal antibody that targets angiopoietin 2 (Ang2). It was designed and developed by Eli Lilly to block angiogenesis as an anti-tumour mechanism. As Ang2 is elevated in acute respiratory distress syndrome (ARDS), Eli Lilly chose to evaluate LY3127804 in patients hospitalised with COVID-19 pneumonia, to ascertain if this approach could reduce the risk of developing ARDS in at risk patients. The COVID study was terminated for futility after around 6 months.
The peptide chain sequences of zansecimab (from its INN submission) are identical to sequences claimed in Eli Lilly's patent WO2015179166A1: sequences 2 and 4 comprise the heavy and light chains of the mAb designated as 'Antibody A' in the patent [1].
No information available.
Summary of Clinical Use Click here for help
Being evaluated in solid tumours. A study in COVID-19 patients was terminated as zansecimab was considered unlikely to be effective.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04342897 A Study of LY3127804 in Participants With COVID-19 Phase 2 Interventional Eli Lilly and Company This trial was terminated in late October 2020 for futility.
NCT02597036 A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Phase 1 Interventional Eli Lilly and Company 2